Nav: Home

Antimalarial being tested as possible Ebola virus drug

November 10, 2016

Fuquay Varina, N.C. (November 10, 2016) - The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc. (CPI) to initiate a partnership with Texas Biomedical Research Institute aimed at repurposing an antimalarial for use against the Ebola virus.

Since 2014, the outbreak of the Ebola virus in West Africa has resulted in 28,657 suspected cases and 11,325 deaths (according to WHO statistics) and highlighted the need for broad-spectrum antiviral drugs for this and other emerging viruses. Data from a published large scale high throughput screen performed by SRI International and Texas Biomedical Research Institute was used to create machine learning models that identified 3 compounds active against the virus in vitro (in a lab, outside of a living organism). This earlier work had suggested that antimalarial compounds, as well as other classes of approved drugs could be of interest for repurposing.

"We used Bayesian machine learning models based on the earlier published dataset to screen a library of more than 2000 drugs and drug-like molecules, which then lead to the discovery that of the 3 compounds identified, a relatively new antimalarial called pyronaridine, approved in Europe had promising activity in vitro and could be worthy of testing in vivo (in a living organism) against the Ebola virus" said Sean Ekins, CEO CPI.

"My lab has screened thousands of compounds against Ebola virus," said Dr. Robert Davey, Interim Chair of Texas Biomed's Department of Virology and Immunology. "This particular compound, pyronaridine, is promising because it is already an approved drug in Europe, has been used in thousands of patients and may have favorable molecular properties that could speed up its transition to clinical testing. We do not currently know the target of the three compounds and there is still considerable research needed."

Dr. Davey is interested in understanding how viruses like Ebola virus penetrate the cell membrane and establish infection. In addition, Dr. Davey's laboratory has developed safe, efficient, high-throughput screening techniques for Ebola virus and performs contract work on testing drugs and compounds against Ebola virus infection in the biosafety level-4 maximum containment laboratory. This work has resulted in exciting findings towards potential drug candidates to combat Ebola virus.

"This collaboration involves Texas Biomedical Research Institute, Stanford Research International and Rutgers University, and we are very grateful to NCATS for funding so we can illustrate how computational approaches can be used to repurpose drugs already approved for other uses and instead use for neglected diseases" said Dr. Ekins.
About Texas Biomedical Research Institute

Texas Biomed is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. Texas Biomed partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers and parasitic diseases responsible for malaria and schistosomiasis. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases. Texas Biomed is home to the Southwest National Primate Research Center, one of seven NIH-supported primate research centers in the United States. For more information on Texas Biomed, go to

About Collaborations Pharmaceuticals, Inc.

Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and infectious diseases. We partner with leading academics and companies to identify and translate early preclinical to clinical stage assets. We have considerable experience in preclinical and computational approaches to drug discovery and toxicity prediction. For more information, please visit

Texas Biomedical Research Institute

Related Ebola Virus Articles:

Mutant live attenuated Ebola virus immunizes non-human primates
Inoculation with an Ebola virus that has mutations in a protein called VP35 does not cause disease and elicits protection in monkeys, researchers show Sept.
Groundbreaking study could lead to fast, simple test for Ebola virus
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus.
RIT professor develops microfluidic device to better detect Ebola virus
A faculty-researcher at Rochester Institute of technology has developed a prototype micro device with bio-sensors that can detect the deadly Ebola virus.
NEJM applying universal standards of care to Ebola virus disease
LSTM's Senior Clinical Lecturer, Dr. Shevin Jacob, is corresponding author on a perspective piece published in the New England Journal of Medicine calling for universal standards of care to be applied in relation to ebola virus disease.
Researchers unlock the biomechanics of how the Ebola virus attaches to its host cell
Lehigh University engineers, working with microbiologists at the University of Iowa, have developed a simple model for virus-host cell interaction driven by Ebola's adhesion to cell surface receptors.
More Ebola Virus News and Ebola Virus Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...